Ramucirumab plus paclitaxel is also a standard second-line treatment option regardless of HER2 status. We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab ...

Enhertu significantly improved overall survival and progression-free survival compared to Cyramza plus paclitaxel in HER2-positive metastatic GC/GEJ patients. The DESTINY-Gastric04 trial established ...

Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast ...

Relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel significantly improved progression-free survival in women with platinum-resistant ovarian cancer.

Fresenius Kabi's ustekinumab biosimilar Otulfi ™ is now commercially available for both subcutaneous and intravenous formulations With this launch, Fresenius Kabi Canada's immunology biosimilar ...

Fresenius Kabi's ustekinumab biosimilar Otulfi™ is now commercially available for both subcutaneous and intravenous formulationsWith this launch, ...

"We are highly encouraged by the robust efficacy signal and the tolerable safety profile observed with onvansertib plus paclitaxel in patients with mTNBC. The majority of the patients were heavily ...

Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three ...

Director and Head of Commercial, Fresenius Kabi Biopharma, Canada. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role ...